Uniqure N.V. (QURE) Stock Price, Quote & News

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 20 240 6000

Website: www.uniqure.com

Address:

Paasheuvelweg 25, Amsterdam, Netherlands

BIOTECH_GURU Sep. 1 at 2:25 PM

$NKTR $QURE $ALMS I told you then, I will tell you now. Psoariasis is what will drive this towards success. Overreaction to a very strict primary/secondary outcome trial in a more rare disease. Buying at these levels Nfa Gltya.

0 · Reply

MABA1 Aug. 31 at 7:53 PM

$QURE behaving as if the data will come out tomorrow. Tightly coiled

0 · Reply

stu4 Aug. 30 at 6:11 PM

$QURE and Matt told his stock broker friends already , his only true profession ..a broker ! CEO! Hardly

0 · Reply

daticecold Aug. 29 at 7:43 PM

$QURE Bears in this stock are so misguided, it is tough to believe. I am disgusted. The good news is, soon all bears will be headed to planned bankruptcy. I've already purchased champagne to be opened and enjoyed at the 4 year data. Have a good weekend everyone!

0 · Reply

Merlintrader Aug. 28 at 7:08 PM

$QURE uniQure stock hub: four-year AMT-130 data due in September, a BLA guided for the third quarter, and what the accelerated approval path still requires https://www.merlintrader.com/uniqure-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=uniqure-stock-hub

0 · Reply

uranumo Aug. 28 at 12:17 PM

$QURE anyone have an idea about the upcoming catalyst? I mean something in depth?

1 · Reply

RealBreakoutTrades Aug. 27 at 4:09 PM

$QURE

0 · Reply

Doozio Aug. 27 at 3:54 PM

So $CLPT gets da $QURE NEXN in HRMY wen all da RSKD goes on?

1 · Reply

daticecold Aug. 27 at 3:40 PM

$QURE In Dr. Sung We Trust.

0 · Reply

CapitalMonk Aug. 26 at 8:03 PM

$QURE Price: $50.95 (-0.20%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±6.33% RSI: 70.0 | Momentum: Strong Momentum Volume: -23.6% vs avg Volatility: 2.65% Support: $39.92 | Resistance: $51.72 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

uniQure price target lowered to $60 from $65 at Barclays

2026-07-29T20:16:22.000Z - 4 weeks ago

Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130

2026-07-29T20:12:08.000Z - 4 weeks ago

uniQure upgraded to Outperform from Peer Perform at Wolfe Research

Jul 29, 2026, 8:30 AM EDT - 4 weeks ago

uniQure Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 4 weeks ago

uniQure Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 4 weeks ago

uniQure Quarterly report: Q2 2026

2026-07-29T11:30:54.000Z - 4 weeks ago

uniQure reports Q2 EPS ($1.22), consensus (71c)

Jul 29, 2026, 7:05 AM EDT - 4 weeks ago

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Jul 22, 2026, 7:05 AM EDT - 5 weeks ago

uniQure to Announce Second Quarter 2026 Financial Results

2026-06-29T10:00:16.000Z - 2 months ago

uniQure price target raised to $80 from $50 at H.C. Wainwright

Jun 25, 2026, 4:10 PM EDT - 2 months ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

2026-06-25T11:26:12.000Z - 2 months ago

uniQure price target raised to $68 from $35 at Mizuho

2026-06-24T01:51:45.000Z - 2 months ago

uniQure 4.95M share Spot Secondary priced at $45.50

Jun 23, 2026, 9:13 PM EDT - 2 months ago

uniQure Announces Pricing of Upsized $225 Million Public Offering

2026-06-23T18:40:00.000Z - 2 months ago

UniQure Stock (QURE) Gains on Public Offering Plans

2026-06-23T15:04:50.000Z - 2 months ago

uniQure rises 7.6%

2026-06-22T20:13:29.000Z - 2 months ago

uniQure announces $150M offering of common stock

Jun 22, 2026, 4:01 PM EDT - 2 months ago

uniQure Announces $150 Million Proposed Public Offering

2026-06-19T11:25:07.000Z - 2 months ago

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

$uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy$

Jun 19, 2026, 7:05 AM EDT - 2 months ago

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

2026-06-18T12:22:32.000Z - 2 months ago

Barclays upgrades uniQure, calls BLA submission ‘major positive’

2026-06-18T11:31:03.000Z - 2 months ago

uniQure price target raised to $70 from $36 at Leerink

2026-06-18T11:18:09.000Z - 2 months ago

uniQure price target raised to $65 from $35 at RBC Capital

2026-06-18T11:12:32.000Z - 2 months ago

uniQure upgraded to Overweight from Equal Weight at Barclays

2026-06-18T10:27:49.000Z - 2 months ago

uniQure price target raised to $46 from $14 at Goldman Sachs

Jun 17, 2026, 12:12 PM EDT - 2 months ago

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

Jun 17, 2026, 11:32 AM EDT - 2 months ago

What made uniQure stock nearly double on Wednesday?

Jun 17, 2026, 10:10 AM EDT - 2 months ago

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

Jun 17, 2026, 7:13 AM EDT - 2 months ago

UniQure gets FDA green light to file for Huntington's gene therapy approval

Jun 17, 2026, 7:05 AM EDT - 2 months ago

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease

May 5, 2026, 8:30 AM EDT - 4 months ago

uniQure Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

uniQure Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

uniQure Quarterly report: Q1 2026

May 5, 2026, 7:05 AM EDT - 4 months ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

Apr 30, 2026, 7:05 AM EDT - 4 months ago

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Apr 28, 2026, 7:05 AM EDT - 4 months ago

uniQure to Announce First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 4 months ago

uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

uniQure Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

uniQure Proxy statement: Proxy filing

Mar 9, 2026, 9:18 AM EDT - 6 months ago

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Mar 5, 2026, 6:01 PM EST - 6 months ago

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

Mar 5, 2026, 2:42 PM EST - 6 months ago

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Mar 5, 2026, 1:11 PM EST - 6 months ago

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

Mar 4, 2026, 11:01 PM EST - 6 months ago

FDA official says UniQure fell short on Huntington's trial, defends new study request

Mar 2, 2026, 10:30 AM EST - 6 months ago

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 6 months ago

uniQure Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:00 AM EST - 6 months ago

uniQure Earnings release: Q4 2025

Mar 2, 2026, 8:00 AM EST - 6 months ago

uniQure Annual report: Q4 2025

Mar 2, 2026, 7:22 AM EST - 6 months ago

FDA tells UniQure study data insufficient for brain disorder therapy application

Mar 2, 2026, 7:05 AM EST - 6 months ago

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

Feb 25, 2026, 6:00 PM EST - 6 months ago

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

Feb 23, 2026, 7:05 AM EST - 6 months ago

uniQure to Announce 2025 Financial Results

Feb 18, 2026, 10:06 AM EST - 6 months ago

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 17, 2026, 8:16 AM EST - 7 months ago

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Feb 6, 2026, 7:05 AM EST - 7 months ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Jan 13, 2026, 7:00 AM EST - 8 months ago

uniQure Slides: Corporate presentation

Jan 9, 2026, 7:05 AM EST - 8 months ago

uniQure Announces Type A Meeting Scheduled with FDA

BIOTECH_GURU Sep. 1 at 2:25 PM

0 · Reply

MABA1 Aug. 31 at 7:53 PM

$QURE behaving as if the data will come out tomorrow. Tightly coiled

0 · Reply

stu4 Aug. 30 at 6:11 PM

$QURE and Matt told his stock broker friends already , his only true profession ..a broker ! CEO! Hardly

0 · Reply

daticecold Aug. 29 at 7:43 PM

0 · Reply

Merlintrader Aug. 28 at 7:08 PM

0 · Reply

uranumo Aug. 28 at 12:17 PM

$QURE anyone have an idea about the upcoming catalyst? I mean something in depth?

1 · Reply

RealBreakoutTrades Aug. 27 at 4:09 PM

$QURE

0 · Reply

Doozio Aug. 27 at 3:54 PM

So $CLPT gets da $QURE NEXN in HRMY wen all da RSKD goes on?

1 · Reply

daticecold Aug. 27 at 3:40 PM

$QURE In Dr. Sung We Trust.

0 · Reply

CapitalMonk Aug. 26 at 8:03 PM

0 · Reply

StockConsultant Aug. 26 at 1:16 PM

$QURE uniQure stock, good day, watch for a top of range breakout at https://www.stockconsultant.com/?QURE Breakout trade WATCH for possible breakout above 51.34 Target: 64.3, 26% Stop: 46.89 Loss: 8.1% P/L ratio: 3.2 : 1 - Excellent BULLISH [Positioning] Intermediate trend bullish, Uptrend. [Timing] Strong bullish 3 day candlestick pattern. [Timing] Good bullish 1 day moneyflow [Timing] breakout watch above 51.34, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] at resistance

1 · Reply

howardlindzon Aug. 26 at 5:08 AM

$QURE another genetic stock that’s working … no idea how to truly track these type of companies

1 · Reply

Redposition Aug. 26 at 3:14 AM

$QURE $5 or $75 🤔

1 · Reply

HypnoTrader Aug. 26 at 2:01 AM

$QURE the stock is rallying in anticipation of a trial read out. That is always a dangerous trade. Such things are never known for sure and a dissapointing result may cause a 70-90% drop. I hope they succeed. I have no position in $QURE but am long $CLPT since forever. $CLPT will move in the same direction, since $QURE is their most promising xlient right now. But they will neither rise nor fall as much as $QURE.

1 · Reply

daticecold Aug. 26 at 1:05 AM

$QURE If I was short this stock, I would be calling my half-rate broker tomorrow to inform them of my impending bankruptcy and certainly the loss of their margin loan. The dumbest traders alive are short this stock, and the most intelligent traders are long waiting patiently for PAYDAY.

0 · Reply

MF__DOOM Aug. 26 at 12:58 AM

$QURE $MRNA $XBI $SPY $QQQ good luck 🍀

1 · Reply

stu4 Aug. 25 at 3:32 PM

$QURE lol, falling , hahaha , the TUT got out, that’s all A swap between houses

1 · Reply

stu4 Aug. 25 at 3:29 PM

$QURE …old , you wind bag ..You are a pumper of Matt’ s You have been here for 3 years , with mouth Readers ..he already sold today He is an options player, a 5,000 dollar millionaire, haha

0 · Reply

stu4 Aug. 25 at 3:11 PM

$QURE

0 · Reply

stu4 Aug. 25 at 3:10 PM

$QURE lol, what TUT wanted out of?? And whom was the buyer ??? Probably Leerink LLC wanted out….they were bankrupt once !!! But better than TRUMP, he did it 10 times

0 · Reply

stu4 Aug. 25 at 3:05 PM

$QURE Says the guy that exited at $25 , lol, 2 years ago His rhetoric is all BS

1 · Reply

stu4 Aug. 25 at 3:02 PM

$QURE He speaks with a forthe tongue ..SATIN

1 · Reply

Market Cap	3.38B
Revenue (ttm)	16.10M
Net Income (ttm)	-198.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,235.84%
Debt to Equity Ratio	0.15

Volume	1,643,000
Avg Vol	1,570,366
Day's Range	N/A - N/A
Shares Out	69.37M
Stochastic %K	44%
Beta	0.92
Analysts	Strong Sell
Price Target	$67.50